Elite in Malignant Peripheral Nerve Sheath Tumor

Dr. Brigitte C. Widemann

Pediatric Hematology Oncology
8906 Bradmoor Dr, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Malignant Peripheral Nerve Sheath Tumor
8906 Bradmoor Dr, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brigitte Widemann is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Widemann is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Adult Soft Tissue Sarcoma, and Thyroidectomy.

Her clinical research consists of co-authoring 212 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 15 articles in the study of Malignant Peripheral Nerve Sheath Tumor.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MD
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

8906 Bradmoor Dr, Bethesda, MD 20817

Additional Areas of Focus

Dr. Widemann has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Natural History Study of Children and Adults With Chordoma
Natural History Study of Children and Adults With Chordoma
Enrollment Status: Recruiting
Publish Date: September 30, 2025
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Selumetinib
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)
Enrollment Status: Completed
Publish Date: December 06, 2023
Intervention Type: Drug, Other
Study Drugs: Selumetinib, Selumetinib Sulfate
Study Phase: Phase 2
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 29, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

208 Total Publications

Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm.
Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm.
Journal: Neuro-oncology advances
Published: July 25, 2025
Similar Doctors
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Christine A. Pratilas
Pediatric Hematology Oncology
Elite in Malignant Peripheral Nerve Sheath Tumor
Dr. Christine A. Pratilas
Pediatric Hematology Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (34.9 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances

Christine Pratilas is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Pratilas is rated as a Distinguished provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy.

Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. Kathryn M. Lemberg
Pediatric Hematology Oncology
Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. Kathryn M. Lemberg
Pediatric Hematology Oncology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (34.9 miles away)
410-502-4340
Languages Spoken:
English
See accepted insurances

Kathryn Lemberg is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Lemberg is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma.

Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. Lindy Zhang
Pediatric Hematology Oncology
Distinguished in Malignant Peripheral Nerve Sheath Tumor
Dr. Lindy Zhang
Pediatric Hematology Oncology
6201 Greenleigh Ave, 
Middle River, MD 
 (45.6 miles away)
Experience:
9+ years
Languages Spoken:
English
See accepted insurances

Lindy Zhang is a Pediatric Hematologist Oncology provider in Middle River, Maryland. Dr. Zhang has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, and Adult Soft Tissue Sarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Widemann's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile